The synthesis and in vivo evaluation of [18F]PF-9811: A novel PET ligand for imaging brain fatty acid amide hydrolase (FAAH)

Nuclear Medicine and Biology

Volumn 39, Issue 7, 2012, Pages 1058-1067

  Skaddan, Marc B ^a   Zhang, Lei ^a   Johnson, Douglas S ^a   Zhu, Aijun ^a   Zasadny, Kenneth R ^a   Coelho, Richard V ^a   Kuszpit, Kyle ^a   Currier, Gwen ^a   Fan, Kuo Hsien ^a   Beck, Elizabeth M ^a   Chen, Laigao ^a   Drozda, Susan E ^a   Balan, Gayatri ^a   Niphakis, Micah ^b   Cravatt, Benjamin F ^b   Ahn, Kay ^a   Bocan, Thomas ^a   Villalobos, Anabella ^a  

^a PFIZER INC   (United States)

^b SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

FAAH; Fluorine 18; Molecular imaging; PET ligand; Positron emission tomography; Rats

Indexed keywords

FATTY ACID AMIDASE; FATTY ACID AMIDASE INHIBITOR; PF 04457845; PF 9811; PF 9811 F 18; RADIOLIGAND; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; DRUG BINDING; DRUG DISTRIBUTION; DRUG POTENCY; DRUG SELECTIVITY; DRUG SYNTHESIS; DRUG UPTAKE; ENZYME ACTIVITY; IN VIVO STUDY; MALE; MOLECULAR IMAGING; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; RADIOACTIVITY; RAT; SIGNAL TRANSDUCTION;

AMIDOHYDROLASES; ANIMALS; BRAIN; CHEMISTRY TECHNIQUES, SYNTHETIC; LIGANDS; MALE; PIPERIDINES; POSITRON-EMISSION TOMOGRAPHY; PYRIDAZINES; RADIOCHEMISTRY; RATS;

EID: 84866013018     PISSN: 09698051     EISSN: 18729614     Source Type: Journal    
DOI: 10.1016/j.nucmedbio.2012.03.011     Document Type: Article

References (36)

1. Ahn K., McKinney M.K., Cravatt B.F. Enzymatic pathways that regulate endocannabinoid signaling in the nervous system. Chem Rev 2008, 108:1687-1707.
2. Di Marzo V. Targeting the endocannabinoid system: to enhance or reduce?. Nat Rev Drug Discov 2008, 7:438-455.
3. Di Marzo V., Bisogno T., De Petrocellis L. Endocannabinoids and related compounds: walking back and forth between plant natural products and animal physiology. Chem Biol 2007, 14:741-756.
4. Pacher P., Batkai S., Kunos G. The endocannabinoid system as an emerging target of pharmacotherapy. Pharmacol Rev 2006, 58:389-462.
5. Devane W.A., Hanus L., Breuer A., Pertwee R.G., Stevenson L.A., Griffin G., et al. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 1992, 258:1946-1949.
6. Cravatt B.F., Giang D.K., Mayfield S.P., Boger D.L., Lerner R.A., Gilula N.B. Molecular characterization of an enzyme that degrades neuromodulatory fatty-acid amides. Nature 1996, 384:83-87.
7. McKinney M.K., Cravatt B.F. Structure and function of fatty acid amide hydrolase. Ann Rev Biochem 2005, 74:411-432.
8. Ezzili C., Otrubova K., Boger D.L. Fatty acid amide signaling molecules. Biorg Med Chem Lett 2010, 20:5959-5968.
9. Lambert D.M., Vandevoorde S., Jonsson K.O., Fowler C.J. The palmitoylethanolamide family: a new class of anti-inflammatory agents?. Curr Med Chem 2002, 9:663-674.
10. Ahn K., Johnson D.S., Cravatt B.F. Fatty acid amide hydrolase as a potential therapeutic target for the treatment of pain and CNS disorders. Expert Opin Drug Discov 2009, 4:763-784.
11. Seierstad M., Breitenbucher J.G. Discovery and development of fatty acid amide hydrolase (FAAH) inhibitors. J Med Chem 2008, 51:7327-7343.
12. Boger D.L., Miyauchi H., Du W., Hardouin C., Fecik R.A., Cheng H., et al. Discovery of a potent, selective, and efficacious class of reversible alpha-ketoheterocycle inhibitors of fatty acid amide hydrolase effective as analgesics. J Med Chem 2005, 48:1849-1856.
13. Mor M., Rivara S., Lodola A., Plazzi P.V., Tarzia G., Duranti A., et al. Cyclohexylcarbamic acid 3'- or 4'-substituted biphenyl-3-yl esters as fatty acid amide hydrolase inhibitors: synthesis, quantitative structure-activity relationships, and molecular modeling studies. J Med Chem 2004, 47:4998-5008.
14. Ahn K., Johnson D.S., Fitzgerald L.R., Liimatta M., Arendse A., Stevenson T., et al. Novel mechanistic class of fatty acid amide hydrolase inhibitors with remarkable selectivity. Biochemistry 2007, 46:13019-13030.
15. Ahn K., Johnson D.S., Mileni M., Beidler D., Long J.Z., McKinney M.K., et al. Discovery and characterization of a highly selective FAAH inhibitor that reduces inflammatory pain. Chem Biol 2009, 16:411-420.
16. Min X., Thibault S.T., Porter A.C., Gustin D.J., Carlson T.J., Xu H., et al. Discovery and molecular basis of potent noncovalent inhibitors of fatty acid amide hydrolase (FAAH). Proc Natl Acad Sci USA 2011, 108:7379-7384.
17. Wang X., Sarris K., Kage K., Zhang D., Brown S.P., Kolasa T., et al. Synthesis and evaluation of benzothiazole-based analogues as novel, potent, and selective fatty acid amide hydrolase inhibitors. J Med Chem 2009, 52:170-180.
18. Mileni M., Johnson D.S., Wang Z., Everdeen D.S., Liimatta M., Pabst B., et al. Structure-guided inhibitor design for human FAAH by interspecies active site conversion. Proc Natl Acad Sci USA 2008, 105:12820-12824.
19. Mileni M., Kamtekar S., Wood D.C., Benson T.E., Cravatt B.F., Stevens R.C. Crystal structure of fatty acid amide hydrolase bound to the carbamate inhibitor URB597: discovery of a deacylating water molecule and insight into enzyme inactivation. J Mol Biol 2010, 400:743-754.
20. Ahn K., Smith S.E., Liimatta M.B., Beidler D., Sadagopan N., Dudley D.T., et al. Mechanistic and pharmacological characterization of PF-04457845: a highly potent and selective fatty acid amide hydrolase inhibitor that reduces inflammatory and noninflammatory pain. J Pharmacol Exp Ther 2011, 338:114-124.
21. Johnson D.S., Stiff C., Lazerwith S.E., Kesten S.R., Fay L.K., Morris M., et al. Discovery of PF-04457845: a highly potent, orally bioavailable, and selective urea FAAH inhibitor. ACS Med Chem Lett 2011, 2:91-96.
22. Felder C.C., Nielsen A., Briley E.M., Palkovits M., Priller J., Axelrod J., et al. Isolation and measurement of the endogenous cannabinoid receptor agonist, anandamide, in brain and peripheral tissues of human and rat. FEBS Lett 1996, 393:231-235.
23. Li W., Sanabria-Bohórquez S., Joshi A., Cook J., Holahan M., Posavec D., et al. The discovery and characterization of [11C]MK-3168, a novel PET tracer for imaging fatty acid amide hydrolase (FAAH). J Labelled Comp Radiopharm 2011, 54:S38.
24. Wyffels L., Muccioli G.G., Kapanda C.N., Labar G., De Bruyne S., De Vos F., et al. PET imaging of fatty acid amide hydrolase in the brain: synthesis and biological evaluation of an 11C-labelled URB597 analogue. Nucl Med Biol 2010, 37:665-675.
25. Wilson A.A., Garcia A., Parkes J., Houle S., Tong J., Vasdev N. [11C]CURB: Evaluation of a novel radiotracer for imaging fatty acid amide hydrolase by positron emission tomography. Nucl Med Biol 2011, 38:247-253.
26. Ling G.L., Winter H., Arends R., Jay G.W., Le V., Young T., et al. Assessment of the pharmacology and tolerability of PF-04457845, an irreversible inhibitor of fatty acid amide hydrolase-1, in healthy subjects. Br J Clin Pharm 2011.
27. Bachovchin D.A., Ji T., Li W., Simon G.M., Blankman J.L., Adibekian A., et al. Superfamily-wide portrait of serine hydrolase inhibition achieved by library-versus-library screening. Proc Natl Acad Sci USA 2010, 107:20941-20946.
28. Cravatt B.F., Wright A.T., Kozarich J.W. Activity-based protein profiling: from enzyme chemistry to proteomic chemistry. Annu Rev Biochem 2008, 77:383-414.
29. Liu Y., Patricelli M.P., Cravatt B.F. Activity-based protein profiling: the serine hydrolases. Proc Natl Acad Sci USA 1999, 96:14694-14699.
30. Egertova M., Giang D.K., Cravatt B.F. A new perspective on cannabinoid signaling: complementary localization of fatty acid amide hydrolase and the CB1 receptor in rat brain. Proc Biol Sci 1998, 265:2081-2085.
31. Thomas E.A., Cravatt B.F., Danielson P.E., Gilula N.B., Sutcliffe J.G. Fatty acid amide hydrolase, the degenerative enzyme for anandamide and oleamide, has selective distribution within the rat central nervous system. J Neuroscience Res 1997, 50:1047-1052.
32. Ueda N., Puffenbarger R.A., Yamamoto S., Deutsch D.G. The fatty acid amide hydrolase (FAAH). Chem Phys Lipids 2000, 108:107-121.
33. Waterhouse R.N. Determination of lipophilicity and its use as a predictor of blood-brain barrier penetration of molecular imaging agents. Mol Imaging Biol 2003, 3:376-389.
34. Desarnaud F., Cadas H., Piomelli D. Anandamide amidohydrolase activity in rat brain microsomes: identification and partial characterization. J Biol Chem 1995, 270:6030-6035.
35. Fay L.K., Johnson D.S., Lazerwith S.E., Morris M.A., Wang L.J., Meyers M.J., et al. Preparation of (hetero)biaryl ether methylidenepiperidinyl ureas as fatty acid amide hydrolase (FAAH) inhibitors 2008, 57-58. Pfizer Products Inc., USA, [WO 2008047229].
36. Wilson A.A., Jin L., Garcia A., DaSilva J.N., Houle S. An admonition when measuring the lipophilicity of radiotracers using counting techniques. Appl Radiat Isot 2001, 54:203-208.